CTCFL and ovarian carcinoma: Using panels of primary patient-derived ovarian cancer cells, OVCA cell lines and healthy cell subsets, we ultimately selected three PRAME TCRs and one CTCFL TCR with potent and specific antitumor reactivity in vitro and in vivo.